International Companies

Novartis snaps up Synnovation's breast-cancer treatment for up to $3bn

By Benjamin Chiou

Date: Friday 20 Mar 2026

(Sharecast News) - Swiss pharma giant Novartis is to pay up to $3bn to Synnovation Therapeutics to acquire a promising breast-cancer treatment that has shown to reduce the unwanted side effects of available medicines.
Novartis is getting its hands on Synnovation's wholly owned subsidiary, Pikavation Therapeutics, which holds a portfolio of...

Sign up for free or to read the full story

Email this article to a friend

or share it with one of these popular networks:


Article Archive

Top of Page